Keytruda is already approved for adjuvant ... a perioperative option in resectable stage IIA to IIIB NSCLC cases. Bladder cancer hopes back on track There was better news for Imfinzi this week ...

The Keytruda/Padcev combination already has accelerated ... of chemotherapy and immunotherapy in patients with metastatic bladder cancer,” said Dr Apolo, who noted that earlier trials of this ...

Good afternoon, everyone. Thank you for standing by. Welcome to CytomX Therapeutics third quarter, 2024 Financial results call. Please be advised that today's call is being recorded. I would now like ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

The promise of incorporating new treatments and predictive biomarkers to select the right patient for the right treatment ...

Investigators assessed whether intravesical BCG is necessary for patients with high-grade T1 nonmuscle-invasive bladder cancer who have unremarkable histology on the second transurethral resection.

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...